Market closedNon-fractional
Larimar Therapeutics/LRMR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Larimar Therapeutics
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
Ticker
LRMR
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Bala Cynwyd, United States
Employees
42
Website
www.larimartx.com
LRMR Metrics
BasicAdvanced
$601M
Market cap
-
P/E ratio
-$0.97
EPS
0.77
Beta
-
Dividend rate
Price and volume
Market cap
$601M
Beta
0.77
Financial strength
Current ratio
17.986
Quick ratio
17.701
Long term debt to equity
1.958
Total debt to equity
2.315
Management effectiveness
Return on assets (TTM)
-17.32%
Return on equity (TTM)
-26.75%
Valuation
Price to book
2.6
Price to tangible book (TTM)
2.6
Price to free cash flow (TTM)
-11.959
Growth
Earnings per share change (TTM)
-5.00%
3-year earnings per share growth (CAGR)
-33.67%
What the Analysts think about LRMR
Analyst Ratings
Majority rating from 6 analysts.
LRMR Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$15M
13.18%
Profit margin
0.00%
NaN%
LRMR Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.19
-$0.21
-$0.30
-$0.27
-
Expected
-$0.20
-$0.22
-$0.25
-$0.24
-$0.31
Surprise
-2.56%
-6.00%
21.26%
14.89%
-
LRMR News
AllArticlesVideos
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia
GlobeNewsWire·2 months ago
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia
GlobeNewsWire·2 months ago
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Larimar Therapeutics stock?
Larimar Therapeutics (LRMR) has a market cap of $601M as of July 27, 2024.
What is the P/E ratio for Larimar Therapeutics stock?
The price to earnings (P/E) ratio for Larimar Therapeutics (LRMR) stock is 0 as of July 27, 2024.
Does Larimar Therapeutics stock pay dividends?
No, Larimar Therapeutics (LRMR) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Larimar Therapeutics dividend payment date?
Larimar Therapeutics (LRMR) stock does not pay dividends to its shareholders.
What is the beta indicator for Larimar Therapeutics?
Larimar Therapeutics (LRMR) has a beta rating of 0.77. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Larimar Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.